Elon Musk, the man who promoted the belief that the builders of the pyramids from space people are coming to bring about a new revolution, about which many do not know clear information, which is the Neuralink company in the treatment of diseases, and the greater goal is to link humans in a broader and more effective way with the developments of artificial intelligence.
Connecting nerves and the human brain with computers
Neuralink is developing a technology that connects nerves and the human brain to computers through electronic chips in the cerebral cortex, where they are implanted through a specialized medical device.
These chips communicate with computers and smartphones, helping to improve human brain functions, thinking, and controlling the rest of the body's organs.
How will the human brain be linked to computers?
The human brain will be connected to computers by installing the chips by a robot operated by a surgeon, this robot designed by the company Neuralink.
The surgeon will make a 2-mm hole in the person's skull, and the chip will block the hole in the human skull.
Initially, the company aims in the short term to provide advanced treatment for diseases related to diseases of the human central nervous system, for which there is no cure such as cases of paralysis, and to treat a wide range of neurological disorders and restore some sensory and motor functions.
In the long run, it will develop into the collection of vital data that warns of the occurrence of heart attacks and strokes before they occur.
Monkeys play the video game "Pong" brilliantly
Several scientists have disputed experiments on 20 monkeys at UC Davis, which enabled one of the monkeys to master the video game Pong.
The opposition of animal rights activists is centered on the harm that can be caused to animals subjected to testing.
They also criticized Neuralink's payment of $1.4 million to the University of California over two years to conduct research, which escalated into a lawsuit against the university demanding the release of more documents about those experiments.
Despite objections to the monkey experiments, Elon Musk revealed during an interview at the Wall Street Journal's CEO Board summit in December 2021 that Neuralink hopes to begin implanting microchips in human brains. As of 2022.
"Neuralink will not suddenly be able to control the nervous system, link it to devices and control people's brains," Musk said.
Musk stressed that he ultimately wants to coexist with artificial intelligence, and that humans will not be left behind by artificial intelligence in the future.
Neuralink's financing sources
The company began its first funding round in 2017 and raised $ 107 million, to be followed by two other rounds, the first in 2019 and the New York Times reported that Elon Musk had invested $ 100 million in the company.
The second was in 2021, led by Dubai-based VY Capital, during which the company raised $207 million, and the company's value amounted to about $1 billion, according to the assessments of the last financing round.
"Neuralink" is still a private company, and Elon Musk represents the company's largest and most important investor, and serves as the CEO, and many founders and some other investors who have participated in financing rounds, including: "Black Bayers", "Exor Seeds" and "Neuralink" invest in the company. Founders Fund".
Investing in unlisted Neuralink can be done by purchasing the company's equity-backed digital tokens, launched by Ambisafe's Orderbook platform, for a minimum of $10.
Where these symbols represent ownership, but indirectly, in the company's shares.
As for the company’s management, Max Hodak took over as CEO of Neuralink in 2017, writing upon leaving the company in a blog post in September 2021: “It wasn’t my decision, there are many pending things I still want to do, but As always, Elon is right, and it's time to go."
Hodak retained his shares in "Neuralink" and stressed that he hopes that his exit will not cause harm to the company. 5555555555555555 Hodak backed the New York-based start-up Synchron — a competitor to Neuralink.
Competition between Synchron and Neuralink
Synchrone preceded its competitor, Neuralink, and obtained the approval of the US Food and Drug Administration to start clinical trials in humans in the United States with the aim of testing its implantable devices in human brains.
The company plans to place a device called a stentrode, which is smaller than a match, in the brain to help paralyzed patients control digital devices.
There are many other companies working in the same field, including Paradromics and Precision Neuroscience Corp.